(Q38579564)

English

The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis

scientific article published on 03 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

0 references

The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

author name string

Wei Wei

1

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Xin Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Ximeng Ma

3

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Dawei Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Zongze Guo

5

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

3 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

125

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

339-349

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

The 2007 WHO classification of tumours of the central nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Advances in the treatment of primary brain tumors: dawn of a new era?

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

New (alternative) temozolomide regimens for the treatment of glioma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Clinical relevance of MGMT in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Inhibition of angiogenesis by non-toxic doses of temozolomide

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Angiogenesis in malignant gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

The efficacy of temozolomide for recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Temozolomide in the treatment of recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

An Australian experience with temozolomide for the treatment of recurrent high grade gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Temozolomide chemotherapy in patients with recurrent malignant gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Extended-schedule dose-dense temozolomide in refractory gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Phase II study of two-weekly temozolomide in patients with high-grade gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Long-term survival with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1920-0

21 January 2018

Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26334318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salvage therapy with temozolomide for recurrent or progressive high-grade gliomas refractory to ACNU [1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride].

1 reference

https://pubmed.ncbi.nlm.nih.gov/26334318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/26334318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26334318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/26334318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26334318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26334318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26334318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-015-1920-0

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38579564&oldid=2201847748"